Serbian start-up company developed a technology for electrocardiograph (ECG) monitoring. On the basis of 3 leads ECG recording, the technology enables reconstruction of 12-lead ECG signals and therefore, it can accurately identify a heart attack. The company is looking for financial and joint venture agreements with industrial partners.
Serbian start-up company and owner of IP rights has developed the remote electrocardiograph (ECG) monitoring technology. The technology enables cardiovascular patients to obtain prompt advice from experienced cardiologists, increasing the probability of survival in the case of a heart attack. Symptoms of cardiovascular disease (CVD) usually appear suddenly and unexpectedly, and often rapidly degenerate into a life-threatening emergency. Patient’s reaction time to these symptoms can make a critical difference to the ultimate medical outcome. Hence, an always available, personal device for detecting all major cardiac conditions would be a significant advance in the timely treatment of CVD - the global leading cause of death. Currently, the cardiovascular handheld diagnostic ECG devices market is growing at a considerable rate. There are two groups of devices: - one ECG lead devices - typically use integrated electrodes - no cables, but can only be used to detect arrhythmia (irregular heartbeats), and cannot be used for AMI (Acute Myocardial Infarction - heart attack) detection where conventional full 12-lead ECG is necessary. - devices with cables - deliver conventional 12-lead ECG by attaching either cable electrodes or specially designed electrode belts. They are supposed to be precisely positioned on the patient’s body. Both ways are uncomfortable, especially for a patient potentially agitated due to AMI. The crucial advantage of this technology is that it has no integrated electrodes and is delivering conventional 12-lead ECG. The technology is highly innovative, smartphone-based, easy to use, individualized and diagnostically accurate. Patients record and transmit their cardiac electrical signals by simply pressing the device against their chest. No wires, no ECG machine and no technician are required. It is based on an easy to use app and hand-held device with 4 integrated ECG electrodes (2 for chest and 2 for thumbs). It is connected to the smartphone via Bluetooth connection. The user-friendly smartphone application has an interactive user interface, controls the recording process, provides real-time signal quality feedback and enables bidirectional connection with the remote central cloud computer server. Despite its simplicity, the technology can accurately monitor a broad range of cardiac conditions, including acute and chronic Coronary Heart Disease (CHD). For these conditions, and specifically heart attack, no other more convenient, user-friendly and accurate outpatient monitoring device exists currently. Central cloud computer server contains information of all registered patients and has an internet connection with a diagnostic center. The stored matrix enables reconstruction of 12-lead ECG signals from the received 3 leads ECG recordings. The reconstructed 12 lead ECG together with the stored 12-lead ECG taken during the calibration is delivered to the diagnostic center being available to the physicians for comparison. It has been shown that the availability of a prior “normal” ECG for comparison can significantly improve the diagnostic accuracy of the ECG in AMI diagnosis, mainly by improving the specificity in AMI detection. All recordings for each patient are stored in a database and are permanently available from the diagnostic center and from the computer, tablet or smartphone of the authorized physicians. The patient’s smartphone is used for authorization and sending feedback about the successful/unsuccessful recording session. The company is seeking financial and joint venture agreements with industrial partners operating in the field of medical technologies and equipment. Financial agreements are sought in order to obtain funding for further development and validation of the technology. Joint venture agreements would include common activities in developing marketable products, technology distribution and providing know-how.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The potential partner should be a company already present on the mobile health market. They should be able to recognise the advantages of this technology and willing to cooperate in the form of financial or joint venture agreement. The potential partner for financial agreement should offer financing for further development, certification and medical validation of the technology. The cooperation via joint venture agreement should include joint activities in developing marketable products and providing support and know-how. Joint ventures with business partners will be considered with the aim of creating a network for technology distribution in Europe and other international markets.
Stage of Development:
Available for demonstration
Patent(s) applied for but not yet granted,Patents granted
Comments Regarding IPR Status:
The technology is protected by the patents on the territory of the Republic of Serbia.